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that T-bet may play a critical role in the differentiation1Department of Neurology
of Th1 cells. In addition, T-bet-deficient mice fail to gen-2 Department of Internal Medicine
erate Th1 cells and spontaneously develop physiologi-3 Center for Immunology
cal and inflammatory changes characteristic of asthma,University of Texas Southwestern Medical Center
a Th2-mediated disease orchestrated by Th2 lympho-5323 Harry Hines Boulevard
cytes (Finotto et al., 2002). T-bet was originally believedDallas, Texas 75390
to mediate its effects via the IL-12/STAT4 pathway
(Szabo et al., 2000; Rengarajan et al., 2000), but more
recent studies have demonstrated that its role in theSummary
production of IFN appears to be mediated by the IFN/
STAT1 pathway (Mullen et al., 2001; Afkarian et al., 2002;As a means of developing therapies that target the
Siebler et al., 2003). Although it was originally speculatedpathogenic T cells in multiple sclerosis (MS) without
that T-bet may be the master regulator of cytokine ex-compromising the immune system or eliciting systemic
pression in Th1 cells, similar to GATA3 in Th2 cells, aside effects, we investigated the use of T-bet-specific
subsequent study has questioned the precise role ofantisense oligonucleotides and small interfering RNAs
T-bet in Th1 cells (Afkarian et al., 2002). Thus, the exact(siRNA) to silence T-bet expression in autoreactive
role of T-bet in the differentiation of naive antigen-spe-encephalitogenic T cells and evaluated the biological
cific T cells into Th1 cells has not been clearly estab-consequences of this suppression in experimental au-
lished. Since many autoimmune diseases are mediatedtoimmune encephalomyelitis, a model for MS. The T-bet-
by Th1 cells, we investigated the role of T-bet and thespecific AS oligonucleotide and siRNA suppressed T-bet
genes it regulates in the differentiation of myelin-specificexpression, IFN production, and STAT1 levels during
T cells into Th1 cells capable of inducing EAE.antigen-specific T cell differentiation. In vitro suppres-
EAE is an inflammatory, demyelinating disease of thesion of T-bet during differentiation of myelin-specific
central nervous system and is a model for the humanT cells and in vivo administration of a T-bet-specific
disease multiple sclerosis (MS). EAE is induced in ro-antisense oligonucleotide or siRNA inhibited disease.
dents by immunization with myelin proteins or peptidesT-bet was shown to bind the IFN and STAT1 promot-
in complete Freund’s adjuvant, or by the transfer ofers, but did not regulate the IL-12/STAT4 pathway.
activated CD4 myelin-specific Th1 lymphocytes intoSince T-bet regulates IFN production in CD4 T cells,
naive recipient animals. Shifting the phenotype of my-but to a lesser extent in most other IFN-producing
elin-reactive T cells from a Th1 to a Th2 phenotype iscells, T-bet may be a target for therapeutics for Th1-
beneficial in the treatment of EAE (Racke et al., 1994,mediated diseases.
1995). However, many of the reagents, such as retinoids,
PPAR agonists, and cyclophosphamide, that have beenIntroduction
used to induce immune deviation affect many different
cell types and signaling pathways, resulting in undesir-Cytokines are the dominant factors directing the differ-
able side effects. We have been investigating whether
entiation of T cells into Th1 and Th2 cells. Upon T cell
we can develop therapeutic agents that specifically tar-
receptor engagement of MHC/peptide complexes, two
get a gene to alter the encephalitogenic potential of
receptors, the IFN and IL-12 receptors, play key roles autoreactive T cells and minimize the effects on other
in the differentiation of naive T cells into Th1 cells. The cell types and other signaling pathways within T cells.
IFN receptor activates a signaling pathway involving To determine if suppression of T-bet may be beneficial
STAT1, while the IL-12 receptor activates a signaling in altering the development of encephalitogenic T cells,
pathway using STAT4. The differentiation of Th2 cells we developed an antisense oligonucleotide (AS oligo)
is mediated by IL-4, which induces the expression of and small interfering RNA (siRNA) specific for T-bet. AS
the transcription factor, GATA3. GATA3 appears to be oligos are small single-stranded DNA sequences that
a master regulator in Th2 cells that transactivates the are usually complementary to the translation initiation
Th2 cytokine genes (IL-4, IL-5, and IL-13). More recently, site of the gene of interest. Hybridization to their target
the transcription factor T-bet has been found to be a mRNA inhibits translation of the transcript by preventing
key regulator of the IFN gene in Th1 cells. T-bet is a the ribosomal complexes from binding to the now dou-
member of the T-box family of transcription factors that ble-stranded translation initiation site or by promoting
contains a highly conserved DNA binding domain, called the degradation of the mRNA by RNase H. siRNAs si-
the T-box, that binds to a core DNA sequence in pro- lence genes utilizing an evolutionarily conserved mecha-
moter regions of a diverse set of genes. T-bet has been nism of degrading mRNA complementary to any double-
found to be expressed in Th1 cells, not Th2 cells (Szabo stranded RNA in a cell. RNA interference is thought to
play a critical role in cellular responses to RNA viruses
and in stabilizing the genome by sequestering repetitive*Correspondence: amy.lovett-racke@utsouthwestern.edu
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Table 1. Sequences of Antisense Oligonucleotides and siRNAs
Gene AS Sequence, 5→3 siRNA
T-bet CTCCACGATGCCCATC 5-UGAUCGUCCUGCAGUCUCUdTdT-3
3-dTdTACUAGCAGGACGUCAGAGA-5
5-CGAACGAGUACCGUACACUdTdT-3
Non-sense (NS) CTATGTCATCCGCTCCAC 3-dTdTGCUUGCUCAUGGCAUGUGA-5
GATA3 AGTCACCTCCATGTCCTC
STAT1 5-AUUCCAUCGAGCUCACUCAdTdT-3
3-dTdTTAAGGUAGCUCGAGUGAGU-5
sequences (Hannon 2002). These gene-silencing tech- using the MBP Ac1-11-specific V2.3/V8.2 transgenic
splenocytes in which the vast majority of T cells recog-niques offer several advantages over gene knockout
and monoclonal antibody technologies for studying nize the peptide. The splenocytes were transfected with
the AS oligos or siRNAs that had been bound to a trans-in vitro and in vivo roles of specific genes. First, mice
that have a specific gene deleted may have altered the fection agent to maximize transfection into the cells.
Transfected splenocytes were activated with MBP Ac1-normal requirements for that protein during develop-
ment, and the observed phenotypes may not be the 11, and nuclear extracts were prepared. Western blot
analysis with anti-T-bet demonstrated that T-bet proteinsame in a normal animal that has a gene suppressed
in vitro or in vivo. Second, the gene is deleted from all expression was induced upon activation with MBP Ac1-
11 and that this induction was inhibited in the activatedcell types, which may make it difficult to determine the
relevance of that gene in particular cell types that may splenocytes that were transfected with the siRNA and
AS oligo specific for T-bet (Figures 1A and 1C). Densi-play a role in the disease or pathway of interest. Third,
monoclonal antibodies do not inhibit the expression of tometry of the T-bet and -actin blots was performed,
and the relative protein expression of T-bet was deter-the protein, but they do interfere with the function of the
protein, and their use is typically limited to membrane mined by normalizing the density of the T-bet bands to
the -actin bands (Figures 1B and 1D). The level ofbound and secreted proteins, not intracellular proteins
such as transcription factors. In the present study, we T-bet expression in mock-transfected TCR V8.2 varies
slightly between mice in the absence of antigen, as seendemonstrate that an AS oligo and siRNA specific for
T-bet can be utilized to target T-bet both in vitro and in Figure 1. Interestingly, when T-bet expression is de-
tectable in the mock-transfected cells without antigenin vivo to define the role of T-bet in the differentiation
of autoreactive T cells and as a potential therapeutic activation, as seen in Figures 1C and 1D, AS-Tbet can
suppress the level of endogenous T-bet in the cells eventarget for Th1-mediated diseases.
in the absence of antigen.
To evaluate the efficiency of the transfection of theResults
AS oligos and siRNAs into the primary splenocyte cul-
tures, the AS oligos and siRNAs were labeled with fluo-Generation of T-bet-Specific Antisense
Oligonucleotides and Small Interfering RNA rescein prior to splenocyte transfection. The cell sus-
pensions were evaluated by fluorescent microscopyTo determine if suppression of T-bet may be beneficial
in altering the development of encephalitogenic T cells, after transfection. The number of total cells versus the
number of fluorescein-labeled cells showed that we con-we developed an AS oligo and siRNA specific for T-bet
(Table 1). Two control AS oligos were also generated, sistently transfected 90% of the nonadherent spleno-
cytes (Figure 2).one specific for GATA3, which would have minimal effect
or may enhance encephalitogenicity of T cells, and one To verify that the inhibition of T-bet resulted in the
suppression of IFNproduction, V8.2 transgenic splen-containing a nonsense sequence (Finotto et al., 2001).
The AS oligos were generated on a phosphorothioate ocytes were transfected with the T-bet-specific AS oligo
and siRNA and activated with MBP Ac1-11, supernatantsbackbone to increase their stability and minimize degra-
dation. The siRNA specific for T-bet contains a 19 base were collected, and IFN production was measured by
ELISA. As seen in Figure 3A, IFN production was sup-sequence within the open reading frame generated with
AA overhangs at the 5 ends. The nonsense siRNA was pressed, but not totally inhibited, in the splenocytes that
were transfected with the T-bet-specific nucleic acids,a random sequence that had no significant sequence
similarity to other genes. verifying that silencing T-bet significantly diminished
IFN production. IFN production increases over timeWe investigated whether these T-bet-specific nucleic
acids were capable of suppressing T-bet expression in in the cells in which T-bet was silenced, but it is not
known whether this IFN is expressed by CD4 T cellsMBP Ac1-11-specific T cells. Splenocytes were isolated
from B10.PL mice that were transgenic for the V8.2 or other immune cells in the splenocyte population.
There was no IL-4 produced when T-bet was silencedT cell receptor chain that recognizes MBP Ac1-11 when
paired with a specific V2.3 T cell receptor chain (Gover- during the primary activation (data not shown).
man et al., 1993). Naive V8.2 transgenic mice have a
precursory frequency of MBP Ac1-11-specific T cells of Silencing T-bet Alters the Encephalitogenicity
of MBP-Specific T Cells1 in 103–104 splenoctyes, this measure is more physio-
logically relevant in terms of the number of T cells in a To determine if suppressing T-bet could alter the en-
cephalitogenic capacity of MBP Ac1-11-specific T cells,population specific for a particular antigen compared to
T-bet in Autoimmune T Cells
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Figure 2. Primary Splenocyte Cultures Can Be Efficiently Trans-
fected with AS Oligos and siRNAs
(A–H) AS oligos and siRNAs were labeled with fluorescein, bound
to a transfection reagent, and then added to primary splenocyte
cultures from a B10.PL mouse. After a 20 hr incubation, the nonad-
herent splenocytes were washed twice and examined by micros-
copy. The number of (A, C, E, and G) fluorescein-labeled cells, as
well as the (B, D, F, and H) total number of cells, was counted inFigure 1. Suppression of T-bet Expression with siRNA and AS Oligo
the same fields. The transfection efficiency was consistently90%.(A–D) Splenocytes from a V8.2 transgenic B10.PL mouse were
transfected with an (A and B) siRNA specific for T-bet or an (C and
D) AS oligo specific for T-bet. The cells were activated with MBP
Ac1-11, and nuclear extracts were prepared at 24 and/or 48 hr In contrast, eight of ten mice in the control groups
postactivation. Protein levels were quantitated, and 30 g for T-bet (nontransfected, siRNA-NS, AS-GATA3) developed EAE.
or 5 g for -actin was loaded per lane of an 10% SDS/PAGE gel.
This demonstrates that silencing T-bet in myelin-reac-(A and C) The proteins were transferred to nitrocellulose membranes
tive T cells not only alters their cytokine production, butand probed with anti-T-bet or anti--actin. (B and D) Densitometry
diminishes their pathogenic potential.was performed, and relative T-bet expression was determined by
normalizing the T-bet to -actin levels. Since it had been previously demonstrated that AS
oligos and siRNAs could be administered intravenously
and exhibit specific biological effects in vivo (Shi et al.,
1994; Finotto et al., 2001; Schlaak et al., 2001; Hadidinaive V2.3/V8.2 transgenic splenocytes were trans-
fected with AS-Tbet, siRNA-Tbet, and control nucleic et al., 2002; Sorenson et al., 2003), the ability of these
T-bet-specific nucleic acids to alter actively inducedacids prior to activation with MBP Ac1-11 in vitro and
were transferred into wild-type B10.PL mice. Only 1 of EAE was evaluated. B6 mice were given 20 or 50 g
siRNA-Tbet, AS-Tbet, AS-GATA3, or PBS via the tail vein6 mice in the AS-Tbet group and 1 of 6 mice in the siRNA-
Tbet group developed clinical signs of EAE (Figure 3B). at the time of immunization with MOG35-55/CFA. All of
Immunity
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the spontaneous proliferation rate in LNC by culturing
these cells in the presence of 3[H]-thymidine for 24 hr
without antigen. The proliferation did not vary between
the mice that received the control siRNA or the T-bet-
specific siRNA (Figure 4E), indicating that silencing T-bet
did not interfere with LNC responding to the immuniza-
tion but did alter the phenotype of the responding cells.
Similarly, we examined LNC and splenocytes at day
13 postimmunization/siRNA or AS oligo treatment. None
of the mice had developed clinical signs of EAE. At
this time point, one would anticipate that the activated
antigen-specific T cells would have migrated into the
spleen. The level of T-bet in the splenocytes from the
mice that received AS-Tbet or siRNA-Tbet was reduced
by 60% and 98%, respectively, compared to the T-bet
levels in the mice that received the AS-NS or siRNA-
NS (Figure 4F). Antigen-specific IFN production and
proliferation were also examined. As seen in Figure 4G,
both the splenocytes and LNC from the AS-NS-treated
mice produced significant amounts of IFN in response
to the antigen. In contrast, there was no antigen-induced
IFN production in the splenocytes of the AS-Tbet- or
siRNA-Tbet-treated mice, and only a modest amount of
IFN produced in LNC at 48 hr compared to the amount
produced in LNC from the AS-NS-treated mice. LNC
from the siRNA-Tbet-treated mice were not evaluated
in this experiment because there were not enough cells
recovered from the lymph nodes in these mice. How-
ever, in similar experiments not shown, there was no
significant production of IL-4, IL-5, IL-10, or IFN in LNC
or splenocytes in the mice that received siRNA-Tbet or
AS-Tbet. At day 13, LNC from all of the groups showed
Figure 3. Silencing T-bet Alters the Phenotype of MBP Ac1-11-Spe- antigen-specific proliferation, but only the splenocytes
cific T Cells from the control mice demonstrated antigen-specific
Splenocytes from a V8.2 transgenic mouse were transfected with proliferation in the splenocyte population (Figure 4H),
AS-Tbet or siRNA-Tbet, and after 24 hr, they were activated with suggesting that the spleens of mice that had T-bet si-
Ac1-11. lenced had fewer antigen-specific T cells or that the
(A) Supernatants from the cultured cells were collected at 24, 48,
phenotype of the antigen-specific T cells was differentand 72 hr postactivation, and IFN levels were measured by ELISA.
than the control-treated mice. Antigen-specific prolifer-(B) V2.3/V8.2 transgenic splenocytes were transfected with
siRNA-Tbet, siRNA-NS, AS-Tbet, AS-GATA3, or nothing prior to ation increased significantly in the splenocytes of the
in vitro activation with Ac1-11, and after 72 hr, 10  106 cells were mice that developed EAE (data not shown). We also
injected i.p. into B10.PL mice. The mice were monitored daily for injected fluorescein-labeled AS oligos and siRNAs into
clinical signs of EAE, and the siRNA-Tbet and AS-Tbet groups had mice i.v. to determine the tissue distribution of these
a significantly reduced incidence of EAE compared to any of the control
small nucleic acids. Fluorescein-labeled cells were seengroups. (siRNA-NS versus siRNA-Tbet, p	 0.0001; AS-GATA3 versus
in the spleen, thymus, kidney, heart, and liver, but theyAS-Tbet, p	 0.0001; siRNA-Tbet versus nontransfected, p	 0.0001;
AS-Tbet versus nontransfected, p 	 0.0001). were not seen in thigh muscle at 5 days postinjection
(data not shown).
The Role of T-bet in the Differentiationthe PBS and AS-GATA3-treated mice developed EAE
(Figure 4A), but disease was suppressed in the siRNA- of Encephalitogenic T Cells Can Be
Bypassed by Exogenous IL-12Tbet- and AS-Tbet-treated mice in a dose-dependent
manner (Figures 4B and 4C). To verify that i.v. adminis- To determine the role that T-bet was playing in the dif-
ferentiation of encephalitogenic T cells, we examinedtration of the T-bet-specific siRNA was suppressing
T-bet in vivo, the draining lymph nodes were removed at whether the differentiation of MBP Ac1-11-specific
T cells in the presence of IL-12 altered the level of T-bet72 hr postimmunization/siRNA administration. Nuclear
extracts were prepared from the cells, and Western blot expression. Naive V2.3/V8.2 transgenic splenocytes
were activated with Ac1-11 in the presence or absenceanalysis was used to determine the level of T-bet expres-
sion. As seen in Figure 4D, T-bet expression was of IL-12. Nuclear extracts were prepared from activated
cells, and the level of T-bet expression was determinedsuppressed 85% in the lymph node cells (LNC) from
the mice that received the siRNA-Tbet compared to the by Western blotting. The splenocytes that were acti-
vated in the presence of IL-12 had similar levels of T-betmice that received the siRNA-NS, demonstrating that
i.v. administration of siRNA-Tbet could effectively sup- expression as the splenocytes that were activated with
antigen only (Figure 5A). To confirm this observation,press T-bet expression in vivo. In addition, we examined
T-bet in Autoimmune T Cells
723
splenocytes were activated in the presence or absence scription factor that upregulates STAT1 expression in
Th1 cells. To verify this observation, T-bet expressionof IL-12 and were stained intracellularly with anti-T-bet.
Flow cytometric analysis showed similar intracellular was suppressed in splenocytes with siRNA-Tbet, and
a chromatin immunoprecipitation assay was used tolevels of T-bet in CD4T cells, regardless of the addition
of IL-12 (Figure 5B). These observations suggest that determine if the STAT1 promoter could still be immuno-
precipitated from activated splenocytes, as seen in Fig-T-bet expression is not altered by the presence of IL-
12 and probably functions in a different segment of the ure 6C. When the splenocytes were transfected with
siRNA-NS, the STAT1 promoter could be amplified inTh1 differentiation pathway.
To further explore this observation, naive V2.3/V8.2 T-bet-specific immunoprecipitated DNA, but the STAT1
promoter could not be amplified from the T-bet-specifictransgenic splenocytes were transfected with AS-Tbet
and siRNA-Tbet prior to activation with Ac1-11 in the immunoprecipitated DNA from the cells that had been
transfected with siRNA-Tbet (Figure 6E). This confirmspresence of IL-12. Supernatants were collected from
the cultured cells, and IFN levels were determined by that T-bet directly binds the STAT1 promoter and regu-
lates STAT1 expression in activated splenocytes.ELISA, demonstrating significant IFN production in all
transfection conditions (Figure 5C). At 72 hr postactiva- To determine if STAT1 may also regulate T-bet tran-
scription in some type of feedback loop to optimize IFNtion, the splenocytes were transferred into B10.PL mice,
and all cells activated in the presence of IL-12 could production, a ChIP assay using anti-STAT1 to precipi-
tate DNA/STAT1 complexes from activated V8.2 splen-transfer disease into recipients, regardless of whether
T-bet was silenced prior to activation (Figure 5D). These ocytes was performed. The 5 end of the T-bet gene
could not be amplified in these experiments (data notdata indicate that T-bet functions independently of IL-
12 and/or upstream of IL-12 in the differentiation of the shown). However, due to the lack of data on the pro-
moter/enhancer region of the T-bet gene, the primerencephalitogenic T cells.
sets that were used may not have been optimal. There-
fore, we developed an siRNA specific for STAT1 andT-bet Regulates the IFN and STAT1 Genes
investigated whether reducing STAT1 expression al-To determine what genes T-bet may directly regulate in
tered T-bet expression. Naive V8.2 splenocytes werethe Th1 differentiation pathway, chromatin immunopre-
transfected with siRNA-STAT1 and activated with MBPcipitation (ChIP) assays were utilized. Naive V8.2 trans-
Ac1-11. Nuclear extracts were prepared and analyzedgenic splenocytes were activated in vitro with MBP Ac1-
for STAT1, T-bet, and -actin protein levels. As seen11 and then fixed with formaldehyde to crosslink T-bet/
in Figure 6F, STAT1 expression in activated cells wasDNA complexes. The cells were sonicated, and anti-T-
reduced by 47% by the siRNA, which is significant givenbet was used to immunoprecipitate the DNA specifically
that STAT1 is constitutively expressed by a variety ofbound to T-bet. The immunoprecipitated DNA was puri-
cell types in the spleen. In addition, T-bet expressionfied, and PCR amplification was used to identify pro-
was reduced by 50% when the splenocytes were trans-moter/enhancer regions of various genes that had been
fected with siRNA-STAT1, confirming the previouslybound to T-bet. As seen in Figure 6A, the IFN could be
published observation that STAT1 regulates T-bet ex-amplified with the IFN promoter primer set #7, verifying
pression (Afkarian, et al., 2002).that the IFN gene may be directly regulated by T-bet
Since it had been reported that IL-12R2 mRNA wasin these autoreactive T cells. Similarly, we immunopre-
not upregulated in T-bet-deficient mice, suggesting thatcipitated DNA bound to STAT1 from antigen-activated
T-bet regulated the IL-12R2 gene (Afkarian et al., 2002),V8.2 cells and amplified the IFN gene with two primer
we investigated whether we could confirm this observa-sets (Figure 6B). We also used STAT1 and STAT4 pro-
tion in our experimental system. First, we performedmoter/enhancer region-specific primers to determine if
ChIP assays on activated V8.2 cells with anti-T-bet andthese genes may be regulated by T-bet. As expected,
attempted to PCR amplify the promoter region of thethe STAT4 gene was not amplified from the DNA precipi-
IL-12R2 gene, but we were not successful (data nottated with the T-bet antibody (data not shown). However,
shown). Given that a negative result in this experimenta primer set specific for the STAT1 promoter region
does not preclude the possibility of T-bet regulatingamplified a segment from T-bet-immunoprecipitated
this gene, we analyzed IL-12R2 protein expression inDNA (Figure 6C). Interestingly, this primer set amplified
whole-cell lysates from V2.3/V8.2 TCR transgenica sequence within the STAT1 gene that contained a
splenocytes that had been transfected with AS-Tbet,T-bet binding domain. This was a surprising observation
siRNA-Tbet, or controls by Western blot, but there wasbecause a previous study demonstrated that STAT1-
very little change in IL-12R2 expression when T-betdeficient T cells could not express T-bet mRNA upon
was silenced (data not shown). This was confirmed byactivation, suggesting that STAT1 was regulating the
ELISA in which the same whole-cell lysates were usedexpression of T-bet (Afkarian et al., 2002). To determine
as the antigen, and antibodies for IL-12R2, T-bet, andif T-bet expression affected STAT1 protein expression,
STAT1 were used to determine the relative change inV8.2 splenocytes were transfected with siRNA-Tbet,
protein expression upon antigen activation. A ratio ofsiRNA-NS, AS-Tbet, or AS-NS or were mock-trans-
approximately 1 was seen for IL-12R2, which reflectsfected, and nuclear extracts were prepared after activa-
no significant change in protein expression in the cellstion with MBP Ac1-11. A Western blot with anti-STAT1
transfected with siRNA-Tbet or siRNA-NS (Figure 6G).was used to determine the level of STAT1 expression
In contrast, there was a 3-fold increase in STAT1 andwhen T-bet was silenced. As seen in Figure 6D, STAT1
T-bet expression in the cells transfected with siRNA-levels were decreased in the splenocytes in which T-bet
had been silenced, suggesting that T-bet may be a tran- NS compared to the cells transfected with siRNA-Tbet,
Immunity
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Figure 4. In Vivo Silencing of T-bet Suppresses the Incidence of Actively Induced EAE
(A–C) B6 mice were immunized with 200g MOG35-55/CFA, and AS-Tbet and siRNA-Tbet were given via the tail vein at the time of immunization.
(A) AS-Tbet, siRNA-Tbet, AS-GATA3 (50 g/mouse), or PBS were given i.v. (PBS versus AS-Tbet, p 	 0.0001; PBS versus siRNA-Tbet, p 	
0.0001; AS-GATA3 versus AS-Tbet, p 	 0.0001; AS-GATA3 versus siRNA-Tbet, p 	 0.0001). (B) B6 mice were given 20 or 50 g siRNA i.v.
(PBS versus siRNA-Tbet, 20 g, p 	 0.0001; PBS versus siRNA-Tbet, 50 g, p 	 0.0001; siRNA-Tbet, 20 g versus siRNA-Tbet, 50 g, p 

0.0674). (C) B6 mice were given 20 or 50 g AS oligo i.v. (PBS versus AS-Tbet, 20 g, p 
 0.0005; PBS versus AS-Tbet, 50 g, p 	 0.0001;
AS-Tbet, 20 g versus AS-Tbet, 50 g, p 
 0.0002).
(D and E) The draining lymph nodes were removed from mice 3 days after they had been immunized and given 50 g siRNA-NS or siRNA-
Tbet. (D) Nuclear extracts were prepared from LNC, 30 g protein was loaded per lane on a 10% SDS/PAGE gel, and Western blot analysis
T-bet in Autoimmune T Cells
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Figure 5. Differentiation of T Cells in the Presence of Exogenous IL-12 Is Not Dependent on T-bet
(A and B) V2.3/V8.2 transgenic splenocytes were activated with Ac1-11 in the presence or absence of 1 ng/ml IL-12. (A) After a 24 or 48
hr stimulation, nuclear extracts were prepared, 30 g protein was loaded per well, and Western blotting with anti-T-bet was used to determine
the amount of T-bet expression. The background expression of T-bet in these nuclear extracts was higher than was seen in V8.2 transgenic
cells (Figure 1), because there are more spontaneously activated cells in the V2.3/V8.2 mice. (B) The activated cells were stained intracellularly
with anti-T-bet and were evaluated by flow cytometry.
(C and D) V2.3/V8.2 transgenic splenocytes were transfected with AS-Tbet, AS-GATA3, AS-NS, siRNA-Tbet, or nothing 24 hr prior to
activation with Ac1-11 in the presence or absence of 1 ng/ml IL-12. (C) The cells were cultured at 2  106 transfected cells/well with 6  106
irradiated, wild-type B10.PL splenocytes, supernatants were collected at 24, 48, and 72 hr postactivation, and ELISA was used to determine
IFN production. (D) The transfected splenocytes that had been activated in the presence of IL-12 were injected i.p. into wild-type B10.PL
mice at 10  106 cells/mouse, and clinical signs of EAE were monitored daily.
verifying that STAT1 and T-bet levels were significantly that has a pathogenic effect in vivo by using two gene-
silencing techniques. We utilized MBP Ac1-11-specificsuppressed when the T-bet gene was silenced.
TCR transgenic T cells that preferentially differentiate
Discussion into Th1 cells upon activation with MBP Ac1-11. For the
majority of in vitro experiments, splenocytes from mice
that expressed only the V8.2 chain of the transgenicThis study demonstrates the significance of T-bet in the
differentiation of Th1 cells in an antigen-specific system TCR were used because the precursor frequency of
with anti-T-bet was performed. T-bet levels were normalized to -actin levels. (E) LNC were plated at 1  105 cells per well in quadruplicate
in 96-well plates, and 50 Ci 3[H]-thymidine was added to each well without antigen. The cells were harvested at 24 hr, and the amount of
3[H]-thymidine incorporation was determined.
(F–H) The draining lymph nodes and spleen were removed from mice 13 days after they had been immunized and given 50 g AS-NS, AS-
Tbet, or siRNA-Tbet. (F) Nuclear extracts were prepared from 15  106 splenocytes or LNC, either 20 (siRNA) or 30 (AS) g/ml was loaded
per lane of a 10% SDS-PAGE gel, and proteins were transferred to nitrocellulose and probed with anti-T-bet by Western blot. Normalization
of the T-bet levels to -actin levels quantitates the change in T-bet expression. (G) The splenocytes and LNC (4  106 cells/well) were cultured
in 24-well plates with or without antigen. Supernatants were collected at 24 and 48 hr, and IFN levels were measured by ELISA. (H) Splenocytes
and LNC from these mice were plated in quadruplicate in 96-well plates at three concentrations and were cultured with and without antigen.
After 72 hr, 50 Ci 3[H]-thymidine was added to each well, and the cells were harvested after an additional 18 hr incubation. The change in
CPM between the antigen-stimulated and the no-antigen controls was determined.
Immunity
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Figure 6. T-bet Regulates IFN and STAT1 Gene Expression during the Differentiation of Naive T Cells
V8.2 transgenic splenocytes (15  106/condition) were cultured with and without Ac1-11 for 24 hr. The cells were then fixed with 1%
paraformaldehyde, resuspended in RIPA buffer, and sonicated, and the supernatant containing the DNA/protein complexes was collected.
Ten percent of the supernatant containing the total DNA was used as a positive control. The remaining supernatant was divided and
immunoprecipitated with anti-T-bet antibody, anti-STAT1, or an isotype control antibody by using Protein A Sepharose beads. The immune
complexes were eluted from the beads, and proteinase K was used to degrade the T-bet bound to the DNA. The DNA was purified by
chloroform/ethanol precipitation, and multiple primers set within the promoter sequence of several genes were used to PCR amplify the gene
of interest.
(A) DNA immunoprecipitated with anti-T-bet from Ac1-11-activated cells was used as the template in PCR reactions using eight primer sets
for the IFN promoter region. One of the four primer sets (#7) shown specifically amplified the IFN gene.
(B) DNA immunoprecipitated with anti-STAT1 from Ac1-11-activated cells was used as the template in PCR reactions using four primer sets
for the IFN promoter region. Two of the four primer sets (#1 and #7) specifically amplified the IFN gene.
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MBP Ac1-11-specific T cells is 1 in 103–104 splenocytes, tion capacity. In contrast to T-bet-deficient mice, no
increase in Th2 cytokines was seen in mice that receivedwhich is a more physiologically relevant number than
the number of splenocytes from V2.3/V8.2 TCR trans- a single dose of AS-Tbet or siRNA-Tbet.
The role of T-bet in experimental models of inflamma-genic mice in which90% of the splenic T cells respond
to MBP Ac1-11. In addition, exogenous cytokines and tory diseases has been studied previously in model sys-
tems. T-bet deficiency was found to protect from Th1-antibodies to cytokines that are often added to T cell
cultures to drive the differentiation of the cells were not mediated experimental colitis in an adoptive transfer
model, and T-bet-deficient mice were found to be moreused in most of these studies; thus, we could access
the extent of T-bet’s role in Th1 differentiation when the susceptible to an actively induced Th2-mediated colitis
(Neurath et al., 2002). This finding suggests that T-betsource of cytokines was limited to the antigen-present-
ing cells and responding T cells. T-bet expression in plays a critical role in these T cell-mediated inflammatory
diseases. Similarly, Con-A-induced liver injury wasovalbumin-specific T cell receptor transgenic cells dif-
ferentiated in vitro demonstrated varied levels of T-bet ameliorated in T-bet-deficient mice (Siebler et al., 2003).
However, T-bet-deficient Balb/c mice immunized withexpression under different Th1-inducing conditions
(Afkarian et al., 2002). Since the primary source of IFN an insulin peptide develop diabetes-related phenotypes
similar to wild-type Balb/c mice, indicating that T-betand IL-12 during the differentiation of Th1 cells in vivo
is the antigen-presenting cells, NK cells, and CD8 does not play a critical role in this inflammatory model
(Melanitou et al., 2003). It has been shown recently thatT cells, we thought that stimulation of splenocytes with
antigen alone provided the most accurate assessment T-bet-deficient mice are resistant to actively induced
EAE and develop a Th2 phenotype (Bettelli et al. 2004).of T-bet’s role in the differentiation of naive cells since
all of these cell populations are present in primary splen- In contrast to these previous studies, we studied the
role of T-bet in T-bet-competent mice by using gene-ocyte cultures. T-bet expression was induced upon acti-
vation of naive V8.2 TCR splenocytes with MBP Ac1- silencing techniques. Suppression of T-bet during the
in vitro differentiation of myelin-reactive T cells dimin-11, as originally observed in T cell clones activated with
PMA/ionomycin or anti-CD3 (Szabo et al., 2000). Both ished the capacity of these cells to cause EAE when
transferred into naive mice. More importantly, in vivothe AS oligo and siRNA specific for T-bet could effec-
tively suppress T-bet protein expression in MBP Ac1- administration of the siRNA or AS oligo specific for T-bet
prevented the onset of actively induced EAE, suggesting11-stimulated V8.2 TCR transgenic splenocytes. IFN
levels were substantially reduced in the splenocyte cul- that T-bet may be a viable target for therapeutic inter-
vention in Th1-mediated diseases.tures that had been transfected with the T-bet-specific
AS oligo or siRNA without any reciprocal induction of Although it was originally reported that T-bet may play
a role in the IL-12/STAT4 signaling pathway in Th1 cellsTh2 cytokines. The transfection efficiency in the nonad-
herent splenocytes was consistently 90%, indicating (Szabo et al., 2000), other studies have implicated T-bet
in the transactivation of IFN via the IFN/STAT1 path-that there was not a preferential transfection of certain
splenocyte subpopulations. way (Mullen et al., 2001; Afkarian et al., 2002; Siebler et
al., 2003). In the MBP Ac1-11-specific T cells, the levelTo determine if silencing T-bet could effectively sup-
press EAE induction in vivo, mice were given a single of T-bet expression was not increased when the cells
were differentiated in the presence of IL-12. In addition,i.v. injection of AS-Tbet or siRNA-Tbet at the time of
immunization, and this injection reduced the incidence when T-bet expression was silenced in Ac1-11-specific
T cells prior to antigen stimulation in the presence ofof disease by as much as 75% depending on the dose.
Ex vivo analysis of the draining LNC and splenocytes IL-12, IFN production and the encephalitogenic capac-
ity of the cells was not diminished, suggesting that T-betdemonstrated suppressed T-bet expression and IFN
production. At day 13, antigen-specific proliferation was was not necessary for the differentiation of Th1 cells
when the IL-12/STAT4 pathway was directly induced. Itseen in LNC, but it was dramatically reduced in the
splenocytes of the AS-Tbet- and siRNA-Tbet-treated is well established that the IL-12/STAT4 pathway plays
a significant role in the differentiation of naive T cellsmice, suggesting that the number of antigen-specific
cells in the spleen was reduced or had an altered pheno- into Th1 cells (Gately et al.,1998). However, the IL-12R2
chain is dependent on the IFN/STAT1 signaling path-type resulting in altered trafficking or reduced prolifera-
(C) DNA immunoprecipitated with anti-T-bet antibody from Ac1-11-activated cells was used as the template in PCR reactions using three
primer sets for the STAT1 promoter region. One of the two primer sets (#1) shown specifically amplified the STAT1 gene.
(D) Naive V8.2 transgenic splenocytes were transfected with AS-NS, siRNA-NS, siRNA-Tbet, or AS-Tbet or were mock-transfected 24 hr
prior to activation with Ac1-11. Nuclear extracts were prepared from the cells after a 24 hr activation, and 30 g protein was loaded per lane
on a 4%–20% gradient SDS/PAGE gel, transferred to nitrocellulose, and probed with anti-STAT1. Densitometry was used to normalize the
STAT1 levels to the -actin levels to quantitate the relative change in STAT1.
(E) V8.2 transgenic splenocytes were transfected with siRNA-NS or siRNA-Tbet prior to activation. Anti-T-bet was used to immunoprecipitate
the T-bet bound DNA from the cells and the STAT1 promoter was PCR amplified by using primer set #1.
(F) V8.2 transgenic splenocytes were transfected with siRNA-NS or siRNA-STAT1 and were activated with MBP Ac1-11 for 48 hr, and nuclear
extracts were prepared. Western blots were performed by using anti-STAT1, anti-T-bet, and anti--actin. Densitometry was used to normalize
the STAT1 and T-bet levels to -actin levels.
(G) Whole-cell lysates from MBP Ac1-11-activated V8.2 splenocytes were used as the target antigen in an ELISA. Anti-IL-12R2, anti-STAT1,
and anti-T-bet were the primary antibodies. The relative change in protein expression was determined by subtracting the background and
then determining the ratio of the OD of the antigen-activated cells to the OD of the no-antigen cells.
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way, and this dependence establishes a dependence of Since it was well established that myelin-specific CD4
the IL-12/STAT4 pathway on the IFN/STAT1 pathway. Th1 cells were the lymphocyte population that trans-
In this study, we found no evidence that T-bet directly ferred EAE to naive recipient animals, it was not antici-
regulated the expression of the IL-12R2 gene. pated that IFN and IFN receptor-deficient mice would
To determine what genes in the Th1 differentiation develop more severe EAE than wild-type mice (Ferber
pathway may be directly transactivated by T-bet, chro- et al., 1996; Willenborg et al., 1996; Chu et al., 2000).
matin immunoprecipitation (ChIP) assays were used. Likewise, administration of anti-IFN to wild-type mice
Using ectopic expression of T-bet, it has been shown exacerbates EAE (Billiau et al., 1988; Duong et al., 1992,
that IFN and IL-12R2 expression was upregulated in 1994; Lublin et al., 1993; Heremans et al., 1996). These
T-bet-expressing cells, but whether this effect resulted mice have a massive expansion of myelin-specific CD4
from directly transactivating these genes or transacti- cells, suggesting that the complete loss of IFN results
vating other genes that subsequently regulate IFN and in a diminished capacity to regulate the autoreactive
IL-12R2 gene expression was not addressed (Afkarian T cells (Chu et al., 2000) and reinforcing the notion that
et al., 2002). To confirm that the IFN gene directly regu- loss of a particular gene from all cell types can have
lates T-bet in activated T cells as recently observed unforeseen side effects. Although these observations
(Cho et al., 2003), V8.2 transgenic splenocytes were indicate that IFN is not essential for the induction of
activated, and the DNA/T-bet complexes were immuno- EAE, they do not negate the fact that encephalitogenic
precipitated from fixed cells with anti-T-bet. An IFN T cells generated in vivo in wild-type mice produce sig-
promoter sequence was amplified by PCR, confirming nificant amounts of IFN or the fact that in vitro suppres-
that T-bet binds to the IFN promoter. Analysis of the sion of IFN production during the stimulation of myelin-
3500 bases upstream of the IFN gene translation initia- specific T cells reduces the encephalitogenic capacity of
tion site identifies several potential T-bet binding sites these cells (Olsson, 1992). Taken together, these studies
based on the T-box consensus DNA binding sequence, would suggest that suppressing IFN production in the
emphasizing the potential of T-bet as a strong transacti- encephalitogenic Th1 cells, while preserving IFN ex-
vator of the IFN gene. The T-bet-precipitated DNA was pression in other cell types, may provide therapeutic
also used as a template for amplification of the STAT1 benefit. Although T-bet is expressed in CD4 Th1 cells,
and STAT4 promoter sequences to determine if T-bet CD8 T cells, NK cells, B cells, and dendritic cells upon
could potentially regulate either of these genes, which activation, the requirement for T-bet for the expression
are known to play significant roles in the IFN receptor of IFN varies significantly between cell types. In T-bet-
and IL-12 receptor signaling pathways, respectively. As deficient mice, IFN is not expressed by CD4 T cells
anticipated, the STAT4 promoter sequence was not am- (Szabo et al., 2002). In contrast, CD8 T cells and B
plified, but a STAT1 promoter sequence was amplified. cells were originally shown to express normal levels of
This STAT1 promoter sequence contained a T-box DNA IFN in T-bet-deficient mice (Szabo et al., 2002). How-
binding sequence, verifying the potential for this STAT1 ever, IFN has more recently been shown to be reduced
promoter sequence as a viable target for T-bet. This in CD8 T cells during antigen-specific activation of
was a surprising observation in light of the previous TCR-transgenic splenocytes deficient in T-bet (Sullivan
finding that T-bet expression was absent in STAT1/ et al., 2003). Similarly, splenic dendritic cells and NK
cells, suggesting that STAT1 expression was necessary cells from T-bet-deficient mice have reduced IFN pro-
for T-bet expression (Afkarian et al., 2002). Suppression duction (Lugo-Villarino et al., 2003; Szabo et al., 2002).
of T-bet with siRNAs resulted in suppressed STAT1, and Murine macrophages do not express T-bet, indicating
suppression of STAT1 with a STAT1 siRNA resulted in that IFN transcription in these cells is regulated by
suppression of T-bet, implying that STAT1 and T-bet other factors (Lugo-Villarino et al., 2003). Therefore, it
may regulate each other. seems that T-bet may be a target for suppressing the
Study of the the roles of the various cytokines, cyto-
development of CD4Th1 cells, while maintaining some
kine receptors, and transcription molecules in the gener-
level of IFN production in other cell types that play a
ation of encephalitogenic Th1 cells using gene knockout
role in EAE. In addition, T-bet may affect other genesmice and monoclonal antibodies has generated conflict-
yet to be identified, directly or indirectly, that may altering data. Mice lacking the IL-12 p40 subunit are pro-
the program of the T cells during activation, which maytected from EAE, whereas mice lacking the IL-12 p35
result in reduced encephalitogenicity.subunit or the IL-12R2 chain remain susceptible to EAE
(Becher et al., 2002; Gran et al., 2002; Zhang et al., 2003).
Experimental ProceduresThe myelin-reactive T cells in the IL-12R2-deficient mice
still produced significant amounts of IFN, although less
Mice and Induction of Experimental
than wild-type mice, suggesting that the IFN/STAT1 Autoimmune Encephalomyelitis
pathway was sufficient to activate encephalitogenic Th1 B10.PL and B6 mice were bred in a barrier animal facility at UT
cells. IL-12 may not be a critical cytokine in EAE, but Southwestern Medical Center. B10.PL mice transgenic for the MBP
IL-23, which shares the p40 subunit with IL-12, may Ac1-11-specific TCR chains V2.3 or V8.2 were a gift from J. Gover-
man (Goverman et al., 1993). The V2.3 and V8.2 transgenic miceactually be mediating the effects originally attributed to
were crossbred in a barrier animal facility at UT Southwestern Medi-IL-12 in EAE (Cua et al., 2003). STAT4-deficient mice are
cal Center.also protected from EAE, but it is uncertain whether
For adoptive transfer experiments, the spleens from V2.3/V8.2
this is due to an impaired signaling in the IL-12/STAT4 transgenic mice (5–10 weeks old) were removed, and single cell
pathway in the T cells or due to the loss of STAT4 in suspensions were prepared. The splenocytes were cultured in 24-
antigen-presenting cells that produce IFN, which acti- well plates at 2  106 cells per well in RPMI 1640 supplemented
with 5% fetal bovine serum, 2 mM L-glutamine, HEPES buffer, 5 vates the IFN/STAT1 pathway (Chitnis et al., 2001).
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105 M 2-ME, and nonessential amino acids. The cells were trans- cells from wild-type B10.PL mice. The protein concentration was
determined by using the BioRad Protein Assay. Immulon II platesfected with AS oligos and siRNAs as described below. Splenocytes
from wild-type B10.PL mice were irradiated with 3000 rads and were coated with 20 g/ml protein in 0.1 M NaHCO3 (pH 8.2) over-
night at 4C. The plates were washed twice with PBS/Tween andcultured in 24-well plates at 6  106 cells per well in RPMI 1640
supplemented as described above, except the fetal bovine serum blocked with PBS/BSA for 2 hr, and anti-IL-12R2, anti-STAT1, and
anti-T-bet were added at 5 g/ml into duplicate wells for 2 hr. Theconcentration was increased to 10% and pencillin/streptomycin
were added at 100 U/ml. MBP Ac1-11 peptide was added to the plates were washed six times with PBS/Tween, and a biotinylated
secondary antibody was added at 2 g/ml for 1 hr. The remaindercultures at 2 g/ml. After 24 hr of transfection of the transgenic
splenocytes and 24 hr of incubation of the irradiated wild-type splen- of the assay was the same as the IFN ELISA. The relative change
in each protein was determined by subtracting the background andocytes with peptide, the transfected cells were washed with HBSS
and were added to the irradiated wild-type splenocytes. The cells determining the ratio of the OD of the activated cells to the OD of
the no-antigen cells.were incubated for an additional 72 hr, then the cells were washed
with PBS twice, and 10  106 activated cells were injected i.p. into
wild-type B10.PL mice. The mice were evaluated daily for clinical Preparation of Nuclear Extracts and Western Blotting
signs of EAE. The following scoring system was used: 0 
 no signs Splenocytes were transfected as described above. At 24 or 48 hr
of disease, 1 
 limp tail, 2 
 moderate hind limb weakness, 3 
 post-antigen activation, the cells were collected (15–20  106 cells/
severe hind limb weakness, 4
 hind limb paralysis, 5
 quadriplegia condition), and nuclear extracts were prepared by using the NE-
or moribund, 6 
 death due to EAE (Racke et al., 1994). PER Nuclear and Cytoplasmic Extraction Kit (Pierce). In brief, the
For actively induced EAE, B6 mice were given 20 or 50 g AS cells were spun down and resuspended in reagent CER I. The cells
oligo or siRNA in 100 l PBS via the tail vein. The mice were then were vortexed for 15 s and incubated on ice for 10 min. CER II was
immunized s.c. with 200 g MOG35-55 peptide emulsified in CFA added to the cells, and cells were vortexed for 5 s, incubated on
per mouse (Difco Laboratories) above the shoulders and flanks. A ice for 1 min, and then vortexed again for 5 s. The tubes were then
200 ng dose of pertussis toxin (List Biological Laboratories) was centrifuged for 5 min at 20,000 g. The supernatants were removed,
given i.p. at the time of immunization, as well as 2 days postimmuni- the reagent NER was added to the pellets, and the tubes were
zation. The mice were monitored daily for clinical signs of EAE. vortexed for 15 s and then incubated on ice for 10 min. The tubes
were vortexed, incubated on ice three more times, and then centri-
fuged for 10 min at 20,000  g.Antisense Oligonucleotides, siRNA, and Transfection
AS oligos generated on a phosphorothioate backbone were pur- Prior to the Western blot, the protein concentration of these ex-
tracts was determined by using the BioRad Protein Assay. The nu-chased from Life Technologies. The siRNAs were purchased as
purified duplexes from Dharmacon RNA Technologies. The se- clear extracts were diluted in 10 SDS loading buffer and boiled
for 3 min. Extracts were electrophorectically separated on 10% (orquences are shown in Table 1.
For in vitro transfection of splenocytes, 2l TransIT-TKO transfec- 4%–20%) SDS-PAGE gels and were transferred to nitrocellulose
membranes. The membranes were blocked with 5% milk in TBS.tion reagent (Mirus) was diluted in 50 l serum-free/antibiotic-free
RPMI 1640 media per well. After a 10 min incubation at room temper- The primary antibody was usually diluted 1:100 in blocking buffer
and was added to the membrane for 2 hr. The membrane wasature, 1 l 40 M siRNA or 2 l 20 M AS oligo was added to 52
l diluted transfection reagent. The AS oligos and siRNAs were washed three times in TBS/Tween. The secondary antibody bound
to HRP was diluted 1:1000 and was added to the membrane for 1incubated with the diluted transfection reagent at room temperature
with gentle agitation for 30 min. The AS oligos or siRNAs were added hr. The membrane was washed three times, and a chemiluminescent
substrate (Santa Cruz Biotechnology, Inc.) was added for 1 min; theto the V8.2 transgenic splenocyte cultures containing 5  106 cells
in 500 l media per well of a 24-well plate and incubated overnight blot was then exposed to film for various times (0.05–10 min). T-bet
antibody, STAT1 antibody, IL-12R2 antibody, goat anti-mouse IgG-at 37C. On the following day, the nonadherent cells were collected
and washed with fresh media. The adherent cells in the plates were HRP, and anti-goat IgG-HRP were purchased from Santa Cruz Bio-
technology, Inc. The density of the bands was determined by usingalso washed once with fresh media. The nonadherent cells were
resuspended in 2 ml media and placed back in their original wells. an AlphaImager (Alpha Innotech Corp.). The data was normalized
by dividing the density of the T-bet or STAT1 band by the densityMBP Ac1-11 peptide was added at 2 g/ml. For V2.3/V8.2 trans-
genic splenocytes, 2  106 splenocytes were placed in each well of the -actin band.
of a 24-well plate. The transfection protocol was the same, except
the cells were placed with wild-type splenocytes (6  106 cells/well) Chromatin Immunoprecipitation Assays
that had been irradiated and cultured with MBP Ac1-11 after the 24 We used a modified version of the technique previously described
hr transfection. (Dedon et al., 1991; Braunstein et al., 1993). V8.2 transgenic spleno-
cytes (10  106 per condition) were stimulated with antigen or no
antigen for 24 hr. The cells were then fixed in media with a finalELISA
For IFN, purified anti-mouse IFN (Pharmingen) was diluted in 0.1 concentration of 1% formaldehyde for 20 min at room temperature.
The cells were then washed twice with PBS and resuspended inM NaHCO3 (pH 8.2) at 2 g/ml. Immunolon II plates (Dynatech Labs)
were coated with 50 l primary antibody per well and incubated lysis buffer. The cells were pulse sonicated for 3 min to shear the
DNA into 400–900 bp lengths. The supernatant containing the DNA/overnight at 4C. The plates were washed twice with PBS/0.05%
Tween 20. The plates were blocked with 200 l 1% BSA in PBS per protein complexes was collected after centrifugation to remove the
cell debris. An aliquot of the supernatant was set aside for a positivewell for 2 hr. The plates were then washed twice with PBS/Tween,
and 100 l supernatants was added in duplicate. The plates were control in the PCR reactions, because all the DNA from the cells is
contained in the supernatant. An antibody known to immunoprecipi-incubated overnight at 4C and washed four times with PBS/Tween.
Biotinylated rat anti-mouse IFN (Pharmingen) was diluted in PBS/ tate the transcription factor of interest, as well as an isotype control
antibody, was added to the supernatant to bind the DNA/transcrip-1% BSA, 100 l of 1 g/ml biotinylated antibody was added to each
well, and plates were incubated at room temperature for 1 hr. The tion factor complexes. All of the antibodies were the same as those
used in the Western blot. After a 24 hr incubation at 4C, protein Aplates were washed six times with PBS/Tween, and 100 l avidin-
peroxidase was added at 2.5 g/ml and incubated for 30 min. The sepharose beads were added and incubated at room temperature
for 2 hr. The beads were washed, and the immune-complexes wereplates were washed eight times with PBS/Tween, and 100 l ABTS
substrate containing 0.03% H2O2 was added to each well. The plate eluted from the beads with SDS/NaHCO3. The formaldehyde cross-
links from the immunoprecipitated DNA/protein complexes, as wellwas monitored for 15–20 min for color development and read at
OD405. A standard curve was generated from the IFN standards, as the total DNA/protein complexes, were reversed by adding 3 M
NaOAc to a final concentration of 0.3 M and incubating at 65Cand the concentration of IFN in the samples was calculated.
For IL-12R2, STAT1, and T-bet, whole-cell lysates were gener- overnight. The DNA was precipitated with EtOH at –20C. The re-
maining protein was degraded by Proteinase K digestion at 42Cated from 2  106 V2.3/V8.2 TCR transgenic splenocytes that
have been activated with MBP Ac1-11 plus 6 106 irradiated feeder for 2 hr. The DNA was purified by phenol:chloroform extraction,
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followed by EtOH precipitation. The DNA was then used as the Chu, C.Q., Wittmer, S., and Dalton, D.K. (2000). Failure to suppress
the expansion of the activated CD4 T cell population in interferontemplate in PCR reactions specific for the gene of interest. Multiple
primer sets that cover the entire promoter/enhancer region of the gamma-deficient mice leads to exacerbation of experimental auto-
immune encephalomyelitis. J. Exp. Med. 192, 123–128.genes of interest were used to minimize missing critical binding
sites. IFN primer sets (5-3) were #1: CCATACGCAGACACCATTG Cua, D.J., Sherlock, J., Chen, Y., Murphy, C.A., Joyce, B., Seymour,
(forward) and TAGAAACACGAGCTCTGGG (reverse), #2: TCTCTTGA B., Lucian, L., To, W., Kwan, S., Churakova, T., et al. (2003). Interleu-
GGTCCTCCATGC (forward) and GCACATTCTGCTACGCTTG (re- kin-23 rather than interleukin-12 is the critical cytokine for autoim-
verse), #3: GAACATAGAACGGTCCCCGT (forward) and TCCTGGTC mune inflammation of the brain. Nature 421, 744–748.
TACAGAGTGAG (reverse), #5: CTGGGTCAAGATAACTGGG (for-
Dedon, P.C., Soults, J.A., Allis, C.D., and Gorovsky, M.A. (1991). Award) and TCAGCCAAAGGCTCAACCA (reverse), and #7: CACGTT
simplified formaldehyde fixation and immunoprecipitation tech-GACCCTGAGTGAT (forward) and GAGGAAACTCTTGGGCTTC (re-
nique for studying protein-DNA interactions. Anal. Biochem. 197,verse). The STAT1 primer sets were #1: CAGGATGGAGGTTCTC
83–90.AACCTG (forward) and GTGAACGGATATCTGCAGCTCC (reverse),
Duong, T.T., Finkelman, F.D., and Strejan, G.H. (1992). Effect of#2: GGAAGTGCTTGTGAGCTATC (forward) and CCATGCTAACCA
interferon-gamma on myelin basic protein-specific T cell line prolif-TCTCTGCC (reverse), and #3: CAGTGGGTAGAAGGTCTTGCTG (for-
eration in response to antigen-pulsed accessory cells. Cell. Immu-ward) and AGTGCATTGGAAAGCTGG (reverse). The PCR conditions
nol. 145, 311–323.were 55C annealing for 1 min, 72C elongation for 1 min, and 94C
denaturing for 1 min for a total of 35 cycles. Duong, T.T., Finkelman, F.D., Singh, B., and Strejan, G.H. (1994).
Effect of anti-interferon-gamma monoclonal antibody treatment on
Flow Cytometric Analysis of Intracellular T-bet the development of experimental allergic encephalomyelitis in resis-
V2.3/V8.2 TCR transgenic splenocytes were cultured at 5  106 tant mouse strains. J. Neuroimmunol. 53, 101–107.
cells/well in a 24-well plate with MBP Ac1-11 at 2 g/ml, Ac1-11  Ferber, I.A., Brock, S., Taylor-Edwards, C., Ridgway, W., Dinisco,
IL-12 at 1 ng/ml, or no antigen for 24 hr. The cells were stained with C., Steinman, L., Dalton, D., and Fathman, C.G. (1996). Mice with
anti-CD4-PE for 30 min and were then permeabilized with 2 FACS a disrupted IFN-gamma gene are susceptible to the induction of
Lysing Solution (Becton Dickinson) supplemented with 0.025% experimental autoimmune encephalomyelitis (EAE). J. Immunol.
Tween 20 for 10 min. The cells were then stained with anti-T-bet- 156, 5–7.
FITC (Pharmingen) for 30 min and were fixed with 4% paraformalde-
Finotto, S., De Sanctis, G.T., Lehr, H.A., Herz, U., Buerke, M., Schipp,hyde. Cells were gated on viable CD4 lymphocytes, and the data
M., Bartsch, B., Atreya, R., Schmitt, E., Galle, P.R., et al. (2001).was analyzed by using Cell Quest software.
Treatment of allergic airway inflammation and hyperresponsiveness
by antisense-induced local blockade of GATA-3 expression. J. Exp.Acknowledgments
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